NetworkNewsBreaks

TuesdayDec 29, 2020 10:15 am

NetworkNewsBreaks – Loop Insights Inc. (TSX.V: MTRX) (OTCQB: RACMF) Shareholder Letter Outlines Highlights of Most Successful Year in History

Loop Insights (TSX.V: MTRX) (OTCQB: RACMF) CEO Rob Anson has released a recent shareholder letter calling 2020 an extraordinary year and outlining the company’s significant accomplishments. A provider of contactless solutions and artificial intelligence ("AI") to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick-and-mortar space, Loop Insights has seen a year full of firsts and noteworthy partnerships, products and financing. The letter provided a review of the highlights for the company, including its selection to join Amazon Web Services Partner Network and the interactive webinar RACMF hosted with Amazon Web Services to showcase Loop’s venue-tracing…

Continue Reading

TuesdayDec 29, 2020 9:33 am

NetworkNewsBreaks – Ideanomics’ (NASDAQ: IDEX) Mobile Energy Global Division Enters Purchase Agreement with JV Controlled by One of China’s Largest Privately Owned Enterprises

Ideanomics (NASDAQ: IDEX) announced that Meihao Chuxing, a joint venture between BYD and Didi, has entered an agreement with its Mobile Energy Global (“MEG”) division to provide an initial 2,000 units of model BYD D1. Alf Poor, Ideanomics CEO, commented, “We are very pleased to work with Meihao Chuxing and BYD to promote the sales of the D1. Supported by a viable government subsidy program, the proliferation of EVs in China is a testament to the value that public and private partnerships can bring to large scale global challenges. We look forward to developing these types of partnerships and the…

Continue Reading

MondayDec 28, 2020 2:53 pm

NetworkNewsBreaks – HempFusion Wellness Inc. Looks to Bright Horizon in the Marketplace

HempFusion Wellness, a leader in the health and wellness cannabidiol (“CBD”) industry, is optimistic about the future of the marketplace despite a 2020 pandemic-driven downturn for hemp and cannabidiol (“CBD”) industries. While products have seen a decrease in sales and farmers have reduced their hemp acreage, there are bright spots on the horizon with both widening legalization and increased awareness as to the benefits of CBD products. HempFusion Wellness is positioned for opportunity as the vitality of the marketplace is renewed, a concept mirrored in its products’ aim to help restore energy and wellness balances to its consumers. A recent…

Continue Reading

MondayDec 28, 2020 2:39 pm

NetworkNewsBreaks – InsuraGuest Technologies Inc. (TSXV: ISGI) Pairs Sales, Outreach with Expansive Broker Networks for Dynamic Growth

InsuraGuest Technologies (TSXV: ISGI), via its wholly-owned subsidiary InsuraGuest Inc., recently signed an Agent Producer Agreement with USI Insurance Services (“USI”), a leading U.S.-based insurance brokerage and consulting firm. Under the agreement, USI will distribute InsuraGuest’s innovative Hospitality Liability coverages through its nationwide network of more than 7,500 professional brokers. A recent article discussing this reads, “This agreement with USI continues a series of partnerships that InsuraGuest has been signing lately to expand the reach of its insurtech platform and insurance services. ‘InsuraGuest continues to attract and execute exciting relationships with nationally recognized leaders in the insurance industry,’ CEO and…

Continue Reading

MondayDec 28, 2020 2:24 pm

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) on Track to Leverage Psychedelics to Target Depression

Cybin (NEO: CYBN), a mushroom life science company, is set to leverage opportunity amid growing research that demonstrates the significant role psilocybin could play in alleviating symptoms of major depression. According to a recent study conducted by Johns Hopkins Medicine and published in “JAMA Psychiatry,” only two doses of psilocybin accompanied with psychotherapy may lead to significant reductions in symptoms in adults with major depression (https://nnw.fm/gHZR3). “The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” stated Alan Davis, PhD., adjunct assistant professor of psychiatry and…

Continue Reading

MondayDec 28, 2020 2:03 pm

NetworkNewsBreaks – Net Element Inc. (NASDAQ: NETE) Positioned Amid Surging Demand in EV Space

Net Element (NASDAQ: NETE), a financial technology company in the process of transforming its business model to become a pure-play electric vehicle (“EV”) manufacturer through a pending merger with privately-held Mullen Technologies Inc., is poised as the EV sector has seen a sharp uptick in consumer demand and investor interest. Rising demand is driven by a combination of improved sector fundamentals coupled with positive industry news. A recent article discussing the company reads, “A potential combined Net Element-Mullen Technologies entity plans to leverage upon the surge in consumer demand within the electric vehicle space through the launch of its initial…

Continue Reading

MondayDec 28, 2020 11:38 am

NetworkNewsBreaks – CB Scientific Inc. (CBSC) Announces Significant Growing Interest in Its my-Cam and my-Cardia Solutions

CB Scientific (OTC: CBSC), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, today announced the addition of dozens of new clinical trials of its my-Cam device and new hospital monitoring contracts through the company’s exclusive authorized distributor, Mango Wellness Co. Ltd. (“MWC”) and My Cardia Thailand Co. Ltd. (“MCT”) in Thailand. According to the update, MWC’s successful participation as an exhibitor at the Royal College of Physicians of Thailand Annual Conference in Pattaya, Thailand, Oct. 29-31, and again at the Thailand Cardiologist Annual Conference in Hua Hin, Thailand, Dec. 10-12, produced overwhelming interest. More…

Continue Reading

MondayDec 28, 2020 11:08 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Syndicated Broadcast

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals’ Investigational New Drug (“IND”) application for its lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme (“GBM”). The IND is now approved and in effect as filed with the U.S. Food and Drug…

Continue Reading

MondayDec 28, 2020 10:33 am

NetworkNewsBreaks – Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) Announces Pricing of $26M Registered Direct Offering

Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision systems, has announced its entry into definitive agreements with investors for the purchase and sale of 6,265,063 of Foresight’s American Depositary Shares (“ADSs”), each at a price of $4.15, per a registered direct offering. The company will secure approximately $26 million in gross proceeds before deducting placement agent fees and other estimated offering expenses. Foresight intends to use the net proceeds for working capital and other general corporate purposes. The closing of the registered direct offering is expected to take place on or about Dec. 30, 2020, subject…

Continue Reading

MondayDec 28, 2020 10:08 am

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures $12M in Registered Direct Offering

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced the closing of its registered direct offering of 3,116,884 shares of its common stock with a single health care-dedicated institutional investor. Genprex secured gross proceeds of $12 million, before deducting commissions and estimated expenses, with the offering priced at-the-market under Nasdaq rules at a price of $3.85 per share. “We believe that the closing of this transaction with a single, health care-dedicated institutional investor is further evidence that the potential of our gene therapies for cancer and diabetes is gaining recognition within the community…

Continue Reading